RCTs included in the analysis
Ref | Author | NSAID | Dose | Indication | Treated group size | Placebo group size | Outcomes |
---|---|---|---|---|---|---|---|
19 | Laerum et al | Diclofenac | 150 mg/day | Recurrent renal colic | 41 | 39 | GI-minor |
25 | Wahlström et al | Diclofenac | 150 mg/day | Heterotopic ossification after hip arthroplasty | 46 | 50 | GI system disorders |
37 | Laurent et al | Diclofenac | 100 mg/day | Proteinuria in glomerular diseases | 14 | 12 | GI-minor |
43 | Bassotti et al | Diclofenac | 150 mg/day | Healthy volunteers | 8 | 8 | GI-minor |
Indometacin | 150 mg/day | 8 | |||||
27 | Reis et al | Diclofenac | 150 mg/day | Heterotopic ossification after hip arthroplasty | 90 | 90 | GI-minor |
34 | Schnitzer et al | Etodolac | 800 mg/day | Knee osteoarthritis | 91 | 90 | GI-minor |
Nabumetone | 1500 mg/day | 89 | |||||
40 | Laine et al | Etodolac | 400 mg bid | Gastrointestinal tolerability | 18 | 16 | GI-major |
Naproxen | 500 mg bid | ||||||
22 | Hoikka et al | Flurbiprofen | 200 mg/day | Heterotopic ossification after hip arthroplasty | 34 | 34 | GI-minor |
30 | Elmstedt et al | Ibuprofen | 1200 mg/day | Heterotopic ossification after hip arthroplasty | 21 | 22 | GI-minor |
45 | Langman et al | Ibuprofen | 2400 mg/day | Osteoarthritis | 1564 | 514 | GI system disorders |
Diclofenac | 150 mg/day | ||||||
Ibuprofen | |||||||
Diclofenac | |||||||
41 | Persson et al | Ibuprofen | 1200 mg/day | Heterotopic ossification after hip arthroplasty | 48 | 47 | GI-minor |
48 | Doyle et al | Ibuprofen | 1200 mg/day | Gastrointestinal tolerability | 833 | 413 | GI-minor |
26 | Schmidt et al | Indometacin | 75 mg/day | Heterotopic ossification after hip arthroplasty | 102 | 99 | GI system disorders |
20 | Kjaersgaard et al | Indometacin | 75 mg/day | Heterotopic ossification after hip arthroplasty | 19 | 22 | Any GI adverse event |
42 | Scott et al | Indometacin | 25 mg/day | Knee osteoarthritis | 202 | 303 | GI-minor |
47 | Eliakim et al | Indometacin | 150 mg/day | Acute musculoskeletal disorders | 65 | 513 | GI-major |
38 | Berry et al | Lornoxicam | 12 mg/day | Knee and hip osteoarthritis | 44 | 42 | GI-minor |
21 | Lemmel et al | Meloxicam | 15 mg/day | Rheumatoid arthritis | 162 | 147 | GI system disorders |
7.5 mg/day | 159 | ||||||
46 | Yocum et al | Meloxicam | 3.75-15 mg/day | Osteoarthritis | 464 | 157 | Any GI adverse event |
Diclofenac | 100 mg/day | 153 | |||||
33 | Lipscomb et al | Meloxicam | 15 mg/day | Gastrointestinal tolerability | 15 | 15 | GI-minor |
Piroxicam | 20 mg/day | 14 | |||||
35 | Patoia et al | Meloxicam | 15 mg/day | Gastrointestinal tolerability | 13 | 13 | GI-severe |
Piroxicam | 20 mg/day | 13 | |||||
36 | Lund et al | Meloxicam | 15 mg/day | Knee osteoarthritis | 134 | 137 | GI-minor |
44 | Dougados et al | Meloxicam | 15/22.5 mg/day | Ankylosing spondylitis | 120 | 121 | GI-major |
Piroxicam | 20 mg/day | 108 | |||||
29 | Simon et al | Naproxen | 500 mg/day | Rheumatoid arthritis | 138 | 101 | GI ulcers |
18 | Gebuhr et al | Naproxen | 750 mg/day | Heterotopic ossification after hip arthroplasty | 28 | 27 | GI system disorders |
49 | Schiff et al | Naproxen | 1000 mg/day | Knee osteoarthritis | 116 | 116 | GI-minor |
31 | Bono et al | Oxaprozin | 1200 mg/day | Tendinitis and bursitis | 43 | 43 | GI-major |
24 | Prupas et al | Tenidap | 40-200 mg/day | Rheumatoid arthritis | 131 | 67 | GI-minor |
23 | Gebuhr et al (2) | Tenoxicam | 40 mg/day | Heterotopic ossification after hip arthroplasty | 35 | 35 | GI system disorders |
28 | Burssens et al | Tenoxicam | 20 mg/day | Heterotopic ossification after hip arthroplasty | 26 | 29 | GI-minor |
10 mg/day | 29 | ||||||
50 | Szpalski et al | Tenoxicam | 20 mg/day | Low back pain | 37 | 36 | GI-minor |
39 | Dougados et al (2) | Ximoprofen | 30 mg/day | Ankylosing spondylitis | 50 | 95 | GI-minor |